Karyopharm Therapeutics Inc.
KPTI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $56,695 | $37,152 | $31,678 | $85,096 |
| - Cash | $37,672 | $38,725 | $38,783 | $62,476 |
| + Debt | $100,028 | $94,802 | $186,703 | $194,524 |
| Enterprise Value | $119,051 | $93,229 | $179,598 | $217,144 |
| Revenue | $44,044 | $37,929 | $30,015 | $30,542 |
| % Growth | 16.1% | 26.4% | -1.7% | – |
| Gross Profit | $41,931 | $36,878 | $28,714 | $29,211 |
| % Margin | 95.2% | 97.2% | 95.7% | 95.6% |
| EBITDA | -$22,560 | -$25,906 | -$12,354 | -$19,604 |
| % Margin | -51.2% | -68.3% | -41.2% | -64.2% |
| Net Income | -$33,127 | -$37,252 | -$23,462 | -$30,780 |
| % Margin | -75.2% | -98.2% | -78.2% | -100.8% |
| EPS Diluted | -3.82 | -4.32 | -2.77 | -3.67 |
| % Growth | 11.6% | -56% | 24.5% | – |
| Operating Cash Flow | $0 | -$18,697 | -$38,984 | -$25,810 |
| Capital Expenditures | $0 | $0 | $0 | $53 |
| Free Cash Flow | $0 | -$18,697 | -$38,984 | -$25,757 |